|
|
News Breaks | | | | January 4, 2013 | | 07:34 EDT |  | BIIB | Biogen submits application to FDA for factor IX therapy for Hemophilia B
Biogen Idec says it recently submitted a Biologics License Application to the U.S. Food and Drug Administration for the marketing approval of recombinant factor IX Fc fusion protein for the treatment of hemophilia B. rFIXFc is the first product candidate in a new class of long-lasting clotting factor therapies that are being developed with the goals of reducing the burden of treatment for this condition and enhancing protection from bleeding. The regulatory submission was based on results from B-LONG, the largest registrational phase 3 clinical study in hemophilia B to date. Biogen Idec’s BLA submission to the U.S. FDA for rFVIIIFc for use in patients with hemophilia A is on track for filing in 1H 2013. | |
|
News For BIIB From The Last 14 Days Check below for free stories on BIIB the last two weeks. |
|
|
| June 17, 2013 | | 08:54 EDT |  | BIIB | Biogen weekly MS drug scripts up 39%, says Citigroup
 Subscribe for More Information | | | June 12, 2013 | | 16:20 EDT |  | BIIB | On The Fly: Closing Wrap
Stocks on Wall Street were lower despite opening sharply higher as the market looked to avoid its first three day losing streak of the year. Downside momentum quickly took hold however, and the averages moved steadily lower through the session, moving to their lows in the final hour of trading but finishing just off those levels. ECONOMIC EVENTS: In the U.S., the MBA's purchase applications composite index rose 5.0% for the week. The U.S. posted a $139B May budget deficit against expectations for a $130B deficit, and compared to a $124.6B deficit a year ago. In Europe, factory production in the 17-nation euro area rose 0.4% in April from March, compared to expectations for it to remain unchanged. COMPANY NEWS: Cooper Tire (CTB) agreed to be acquired by India's Apollo Tyres for $35.00 per share in cash, or $2.5B. Cooper shares surged $10.10, or 41.12%, to $34.66 to trade near $34.50 following the deal announcement, while peer Goodyear Tire (GT) advanced about 33c, or 2.26%, to $14.93... Live Nation (LYV) shares gained $2.33, or 16.84%, to $16.17 after the company announced it prevailed in an arbitration ruling related to a ticketing license software agreement... MAJOR MOVERS: Among the notable gainers was Ulta Salon (ULTA), up $12.51, or 14.87%, to $96.64 following its quarterly earnings report. Also higher was Health Management (HMA), up $1.58, or 11.34%, to $15.51 after Glenview Capital said in a filing it is seeking to repeal a provision that prevents entities from holding more than 15% of the company's stock and saying it would look to nominate candidates to the company's board. Among noteworthy losers was Biogen (BIIB), down $16.48, or 7.39%, to $206.55 after the stock was downgraded to Neutral from Buy at Citigroup, which cited concerns that EU medical regulators are unlikely to approve the company's multiple sclerosis treatment. Also lower were U.S.-listed shares of Vodafone (VOD), down 71c, or 2.47%, to $28.12 after the company confirmed it approached Kabel Deutschland about a possible deal. INDICES: The Dow was down 126.79, or 0.84%, to 14,995.23; the S&P 500 was down 13.61, or 0.84%, to 1,612.52; the Nasdaq was down 36.52, or 1.06%, to 3,400.43. | | | 10:31 EDT | | BIIB | Biogen retreats after analyst cuts rating to Neutral
Subscribe for More Information | | | 10:14 EDT |  | BIIB | On the Fly: Downgrade Summary
Subscribe for More Information | | | 07:38 EDT | | BIIB | Biogen price target raised to $268 from $219 at Brean Capital
Subscribe for More Information | | | 06:01 EDT | | BIIB | Biogen downgraded to Neutral from Buy at Citigroup
Subscribe for More Information | | | June 11, 2013 | | 11:47 EDT |  | BIIB | Deutsche Bank's biotech analyst holds an analyst/industry conference call
Biotech Analyst Karnauskas discusses Biogen's (BIIB) treatment for Multiple Sclerosis, Tecfidera, as well as reviewing IMS Tecfidera data, on an Analyst/Industry conference call to be held on June 11 at 3 pm. | | | June 10, 2013 | | 07:40 EDT | | BIIB | Leerink's biotech analyst holds analyst/industry conference call on ASCO
Subscribe for More Information | | | June 7, 2013 | | 07:13 EDT | | BIIB | Biogen shares should be bought on recent weakness, says RBC Capital
Subscribe for More Information | | | June 5, 2013 | | 14:08 EDT | | BIIB | Deutsche Bank sees upside to Biogen's Quick-Start program
Subscribe for More Information | | |
|
|
|
|
|
|
